Vaginal Cytomegalovirus Shedding before and after Initiation of Antiretroviral Therapy in (original) (raw)
Related papers
Vaginal Cytomegalovirus Shedding Before and After Initiation of Antiretroviral Therapy in Rakai
2016
Vaginal shedding of cytomegalovirus (CMV) DNA was deter-mined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herpes simplex virus 2, and CMV starting antiretroviral therapy (ART) during a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Vaginal CMV was detected in 75 of 96 women (78.0%) and 379 of 1080 individual visits (35.1%). ART status, higher HIV RNAviral load before ART initiation, and younger age were significantly associated with increased frequency of CMV shedding (P <.01). Compared to pre-ART, CMV shedding peaked from month 2 to month 4 after ART initiation, suggesting possible immune reconstitution in-flammatory syndrome. Further studies need to determine the clinical significance of asymptomatic CMV shedding. Keywords. acyclovir; antiretroviral therapy (ART); cyto-
The Journal of infectious diseases, 2015
Vaginal shedding of CMV DNA was determined among 96 women co-infected with HIV, HSV-2 and CMV starting anti-retroviral therapy (ART) during a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Vaginal CMV was detected in 75 of 96 women (78.0%) and 379 of 1080 individual visits (35.1%). ART status, higher HIV viral load and younger age were significantly associated with increased frequency of CMV shedding (p<0.01), Compared to pre-ART, CMV shedding peaked from month two to four after ART initiation suggesting possible immune reconstitution inflammatory syndrome. Further studies need to determine the clinical significance of asymptomatic CMV shedding.